- Home
- AMBQ vs RIGL Comparison
AMBQ vs RIGL Comparison
Compare AMBQ & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMBQ | RIGL |
|---|---|---|
| Founded | 2010 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 594.9M | 564.7M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | AMBQ | RIGL |
|---|---|---|
| Price | $43.60 | $26.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $42.20 | ★ $45.67 |
| AVG Volume (30 Days) | 298.0K | ★ 336.0K |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | N/A | ★ 0.44 |
| Revenue | N/A | ★ $294,282,000.00 |
| Revenue This Year | $41.81 | N/A |
| Revenue Next Year | $27.98 | $12.75 |
| P/E Ratio | ★ N/A | $59.34 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $22.12 | $17.67 |
| 52 Week High | $43.06 | $52.24 |
Technical Indicators
Market Signals| Indicator | AMBQ | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 73.45 | 31.86 |
| Support Level | $28.11 | $24.84 |
| Resistance Level | N/A | $31.26 |
| Average True Range (ATR) | 2.35 | 1.42 |
| MACD | 0.52 | -0.55 |
| Stochastic Oscillator | 99.07 | 5.13 |
Price Performance
Historical ComparisonAbout AMBQ Ambiq Micro Inc.
Ambiq Micro Inc is a fabless semiconductor company that has developed technology based on a patented Sub-threshold Power Optimized Technology (SPOT) platform that significantly reduces the amount of power consumed by integrated circuits. It is a pioneer and provider of ultra-low power semiconductor solutions designed to address the significant power consumption challenges of general purpose and AI compute - especially at the edge.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.